Skip to content
Screener

Tandem Diabetes Care TNDM Accounts Receivable, Credit Loss Expense (Reversal)

Accounts Receivable, Credit Loss Expense (Reversal) at other companies

Insulet logo
InsuletPODD
$400K0.0%
Senseonics Holdings, Inc. logo
Senseonics Holdings, Inc.SENS
$613K+163%
Medtronic logo
MedtronicMDT
Beta Bionics logo
Beta BionicsBBNX
InfuSystem Holdings logo
InfuSystem HoldingsINFU
Tempus AI, Inc. logo
Tempus AI, Inc.TEM

Other financials

Income statement

See full
Revenue$254.6M+5.8%
Gross profit$144.8M+15.0%
Operating income-$13.8M+73.4%
Net income-$21.2M+59.6%
EPS (diluted)-$0.31+60.3%

Balance sheet

See full
Cash & equivalents$62.8M-2.0%
Total debt$739.3M+64.6%
Total equity$130.4M-2.2%
Total assets$1.2B+31.8%

Cash flow

See full
Operating cash flow-$34.6M-265%
CapEx$4.1M-34.7%
Free cash flow-$38.7M-146%

Valuation

See full
Market cap$1.59B+132%
Enterprise value$2.26B+112%
P/S1.5×+0.8×

Profitability

See full
Gross margin56%+3.5pp
Operating margin-4.4%-1.9pp
Net margin-6.1%-2.5pp
FCF margin-0.8%-0.4pp

Returns & leverage

See full
Return on equity-48%-17.5pp
Debt / equity5.7×+2.3×
Current ratio3.2×+0.7×

Where this comes from

Reported directly by Tandem Diabetes Care in its filing.

Tagged under the XBRL concept us-gaap:ProvisionForDoubtfulAccounts.

The source filing: Tandem Diabetes Care’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001438133-26-000125
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Balance at beginning of the period$6,912$7,125$8,393$7,251
Provision for expected credit losses3,2492,1465,3583,577
Write-offs and adjustments, net of recoveries(2,268)(3,176)(5,858)(4,733)
Balance at end of the period$7,893$6,095$7,893$6,095

Item 1. Financial Statements.

FAQ

What is Tandem Diabetes Care's accounts receivable, credit loss expense (reversal)?
Tandem Diabetes Care (TNDM) reported accounts receivable, credit loss expense (reversal) of $3.25M in Q2 2026.
How has Tandem Diabetes Care's accounts receivable, credit loss expense (reversal) changed year-over-year?
Tandem Diabetes Care's accounts receivable, credit loss expense (reversal) increased by 51.4% year-over-year, from $2.15M to $3.25M.
What is the long-term trend for Tandem Diabetes Care's accounts receivable, credit loss expense (reversal)?
Over 4 years (2021 to 2025), Tandem Diabetes Care's accounts receivable, credit loss expense (reversal) has grown at a 42.0% compound annual growth rate (CAGR), from $2.33M to $9.48M.
What does accounts receivable, credit loss expense (reversal) mean?
Accounts Receivable, Credit Loss Expense (Reversal)

Ask your AI about Tandem Diabetes Care's accounts receivable, credit loss expense (reversal).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude